Total study sample (N = 100) | |
---|---|
Usual care - ACNs in-home assessment | |
Vital signs | |
Respiratory rate, breaths/min | |
Median (IQR) | 21(18–24) |
Range | 11–50 |
Saturation, % | |
Median (IQR) | 96(92–99) |
Range | 77–100 |
Systolic blood pressure, mmHg | |
Median (IQR) | 133 (117–143) |
Range | 81–208 |
Diastolic blood pressure, mmHg | |
Median (IQR) | 74 (67–80) |
Range | 49–113 |
Heart rate, beats/min | |
Median (IQR) | 81 (71–92) |
Range | 44–116 |
Body temperature | |
Median (IQR) | 36.9 (36.6–37.4) |
Range | 35.7–40 |
GCS | |
Median (IQR) | 15 (15–15) |
Simple POCT | |
C-Reactive protein, mg/L | |
Median (IQR) | 24 (5.3–57) |
Range | 0.6–171 |
Haemoglobin, mmol/L | |
Median (IQR) | 7.4 (6.6–8.1) |
Range | 0.1–10.2 |
Presumptive diagnoses, made by the acute nurse, n | |
Pneumonia | 20 |
Viral infection | 18 |
Urine infection | 5 |
Infection, unclear focus | 6 |
AE-COPDb | 15 |
Otherc | 36 |
Intervention – Results from Extended POCT | |
Feasibility of extended POCT, n | |
FLUS | 100 |
Creatinine, electrolytes, leucocytes with differential count | 89 |
PCR for upper respiratory pathogens | 79 |
Urine flow cytometry | 4 |
FLUS, n | 100 |
Patient positioning | |
8 scanning zones | 28 |
14 scanning zones | 72 |
Normal | 36 |
Pneumothorax | ≤ 3a |
Interstitial syndrome | 8 |
Pleural Effusion | 32 |
Unilateral | 25 |
Bilateral | ≤ 3a |
Simple | 30 |
Complex | ≤ 3a |
Small | 26 |
Moderate | 3 |
Large | 3 |
Pneumonia, n | 25 |
Consolidated lung tissue | ≤ 3a |
Dynamic bronchoaerograms | ≤ 3a |
Focal B-lines | 7 |
Focal B-lines, fragmented and thickened visceral pleura, and pleural effusion | 15 |
Other pathologies, n | 16 |
Thickened parietal pleura | 7 |
Uncharacteristic lung consolidations | 6 |
Tumour/suspected malignancy | 3 |
Venous blood samples, n | 89 |
Creatinine, µmol/L | |
Median (IQR) | 80 (66–118) |
Range | 24–281 |
Na+, mmol/L | |
Median (IQR) | 138 (136–140) |
Range | 126–144 |
K+, mmol/L | |
Median (IQR) | 4 (3.7–4.2) |
Range | 3.2–5.3 |
Blood Urea Nitrogen (BUN), mmol/L | |
Median (IQR) | 7.7 (6.2–10.5) |
Range | 1.8–26.5 |
Total leucocytes, 109/L | |
Median (IQR) | 9.4 (7.3–12,1) |
Range | 1.6–25 |
Neutrophils, 109/L | |
Median (IQR) | 5.1 (3.9–7.7) |
Range | 0.3–19 |
Lymphocytes, 109/L | |
Median (IQR) | 2.3 (1.8–2.8) |
Range | 0.8–5.2 |
Monocytes, 109/L | |
Median (IQR) | 0.6 (0.4–0.7) |
Range | 0–1.6 |
Eosinophils, 109/L | |
Median (IQR) | 0.3 (0.2–0.6) |
Range | 0–4 |
Basophils, 109/L | |
Median (IQR) | 0 (0–0.1) |
Range | 0–0.9 |
Biofire filmarray, n | 79 |
Respiratory pathogens detected | ≤ 3a |
Urine samples, n | 4 |
> 105 BACT/ml | ≤ 3a |
Primary care physician contact | |
Primary care Physician, n | |
Doctor reached by phone, | 61 |
Secretary reached by phone | 17 |
No phone contact | 22 |
Initiated treatment during in-home-assessments, n | 48 |
Antibiotic, oral, no (%) | 18 (37) |
Diuretics, oral, no (%) | 3 (6) |
Acute hospital admission following in-home assessments, no (%) | 21 (43) |
Other treatmentsd, no (%) | 12 (25) |
Planned follow-up in-home assessment by ACN | |
Planned new in-home assessment in 3 days | 15 |